ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,969.34
0.35%
Dow Jones
44,296.51
0.97%
US Dollar vs MXN
20.4285
0.00%
Brent Oil
74.65
0.00%
Bitcoin
97,859.04
-1.19%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Hemogenyx Pharmaceuticals Plc (HEMO)

  7. Hemogenyx Pharmaceuticals Plc (HEMO) Noticias

HEMO

Hemogenyx Pharmaceuticals (HEMO)

Hemogenyx Pharmaceuticals Plc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:HEMO
FechaHoraFuenteTítuloSímboloCompañía
22/11/202406:49RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Notice of Extraordinary General MeetingLSE:HEMOHemogenyx Pharmaceuticals Plc
22/11/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC IRB Approval for Phase I Clinical TrialLSE:HEMOHemogenyx Pharmaceuticals Plc
11/11/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Institutional InvestmentLSE:HEMOHemogenyx Pharmaceuticals Plc
30/10/202406:09Alliance NewsAlliance NewsIN BRIEF: Hemogenyx to launch myeloid leukemia treatment phase 1 trialLSE:HEMOHemogenyx Pharmaceuticals Plc
30/10/202402:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Schedule for Phase I Clinical Trial OpeningLSE:HEMOHemogenyx Pharmaceuticals Plc
02/10/202405:19RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Strategic Investment from Prevail Partners, LLCLSE:HEMOHemogenyx Pharmaceuticals Plc
27/09/202412:25Alliance NewsAlliance NewsHemogenyx Pharmaceuticals loss narrows amid reduced expensesLSE:HEMOHemogenyx Pharmaceuticals Plc
27/09/202409:55Alliance NewsAlliance NewsEARNINGS: Clean Power Hydrogen loss widens; Invinity loss narrowsLSE:HEMOHemogenyx Pharmaceuticals Plc
27/09/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Half-year ReportLSE:HEMOHemogenyx Pharmaceuticals Plc
09/09/202416:03Alliance NewsAlliance NewsTRADING UPDATES: Light Science Technologies wins two new contractsLSE:HEMOHemogenyx Pharmaceuticals Plc
09/09/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC FLT3 Assay Ready for Phase I Trials at MD AndersonLSE:HEMOHemogenyx Pharmaceuticals Plc
02/09/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC CDX Development UpdateLSE:HEMOHemogenyx Pharmaceuticals Plc
28/08/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Presentation at CBD S&T ConferenceLSE:HEMOHemogenyx Pharmaceuticals Plc
29/07/202401:00RNS Non-RegulatoryHemogenyx Pharmaceuticals PLC Macrophage-Directed Therapies Summit PresentationLSE:HEMOHemogenyx Pharmaceuticals Plc
27/06/202410:39RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Result of Annual General MeetingLSE:HEMOHemogenyx Pharmaceuticals Plc
17/06/202413:55Alliance NewsAlliance NewsIN BRIEF: Hemogenyx Pharmaceuticals updates on leukemia treatmentLSE:HEMOHemogenyx Pharmaceuticals Plc
17/06/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Operations UpdateLSE:HEMOHemogenyx Pharmaceuticals Plc
03/06/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Posting of Annual Report & Notice of AGMLSE:HEMOHemogenyx Pharmaceuticals Plc
25/04/202406:19Alliance NewsAlliance NewsEARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payoutLSE:HEMOHemogenyx Pharmaceuticals Plc
25/04/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Final ResultsLSE:HEMOHemogenyx Pharmaceuticals Plc
28/03/202402:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Total Voting RightsLSE:HEMOHemogenyx Pharmaceuticals Plc
29/02/202408:04Alliance NewsAlliance NewsHemogenyx Pharmaceuticals raises money for leukaemia treatmentLSE:HEMOHemogenyx Pharmaceuticals Plc
29/02/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC Placing to Raise US$4.2 millionLSE:HEMOHemogenyx Pharmaceuticals Plc
16/02/202405:27Alliance NewsAlliance NewsHemogenyx shares rise on potential for CBR to treat brain diseasesLSE:HEMOHemogenyx Pharmaceuticals Plc
16/02/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC CBR Brain DeliveryLSE:HEMOHemogenyx Pharmaceuticals Plc
14/02/202404:14Alliance NewsAlliance NewsHemogenyx says CBR can be used intranasally to treat viral infectionsLSE:HEMOHemogenyx Pharmaceuticals Plc
14/02/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC CBR Intranasal DeliveryLSE:HEMOHemogenyx Pharmaceuticals Plc
09/02/202404:00Alliance NewsAlliance NewsIN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial holdLSE:HEMOHemogenyx Pharmaceuticals Plc
09/02/202401:00RNS Regulatory NewsHemogenyx Pharmaceuticals PLC FDA Consents to Phase I Trials of HEMO-CAR-TLSE:HEMOHemogenyx Pharmaceuticals Plc
02/02/202404:44Alliance NewsAlliance NewsIN BRIEF: Hemogenyx hails US patent application progressLSE:HEMOHemogenyx Pharmaceuticals Plc
 Showing the most relevant articles for your search:LSE:HEMO

Su Consulta Reciente

COIN
AVAXUSD
Avalanche
NYSE
VZ
Verizon Communications
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
AXP
American Express
NYSE
NKE
Nike
NASDAQ
GOOGL
Alphabet
NASDAQ
AAPL
Apple
NYSE
MCD
McDonalds
FX
EURMXN
Euro vs MXN
NASDAQ
MSFT
Microsoft
COIN
ETHUSD
Ethereum
CCOM
SILVER
SILVER
USOTC
BASFY
BASF (QX)
COIN
XRPUSD
Ripple
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados